Authors: Barrett J.F.; Dougherty T.J.

Source: Expert Opinion on Investigational Drugs, Volume 13, Number 6, 1 June 2004 , pp. 715-721(7)

Publisher: Informa Healthcare

Abstract:

Over 100 senior researchers and managers from academic and industrial research organisations attended this 2-day annual international discovery summit on antibacterial R&D. A number of firms, particularly biotechnology firms, presented compounds that are advancing through clinical development. In addition, areas for basic research and development included metallo--lactamases, ribosomal structural studies and phage-selected targets were described.

Keywords: antibacterial; antibiotic; genomics; pipeline; resistance emergence; targets

Document Type: Meeting report

DOI: http://dx.doi.org/10.1517/13543784.13.6.715

Publication date: 2004-06-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Barrett J.F. ;  Dougherty T.J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers